http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
- 中文 을 입력하시려면 zhongwen을 입력하시고 space를누르시면됩니다.
- 北京 을 입력하시려면 beijing을 입력하시고 space를 누르시면 됩니다.
RISS 인기검색어
- 검색키워드
- 저자 : Lorena Calderón-Pérez (검색결과 2 건)
- 무료
- 기관 내 무료
- 유료
-
Acute Effects of Turmeric Extracts on Knee Joint Pain: A Pilot, Randomized Controlled Trial
Lorena Calderón-Pérez,Elisabet Llauradó,Judit Companys,Laura Pla-Pagà,Noemí Boqué,Francesc Puiggrós,Rosa-M Valls,Anna Pedret,Josep Manuel Llabrés,Lluís Arola,Rosa Solà 한국식품영양과학회 2021 Journal of medicinal food Vol.24 No.4
Turmeric extracts (TEs) have been shown to be suitable as a pain treatment for human joint arthritis. In a pilot, randomized clinical trial, 68 individuals with mild/moderate knee joint pain (KJP) consumed a new formulation of water-soluble TEs and insoluble curcuminoids (B-Turmactive®) or brewer's yeast as a placebo for 1 week. Our hypothesis was that B-Turmactive would have a short-term analgesic effect on KJP measured by the self-reported Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC). After 3 days and 1 week, both treatments reduced pain when walking on a flat surface (P < .01), going up or down stairs (P < .001), and sitting or lying (P < .05), but only B-Turmactive reduced pain at night while in bed and in an upright standing position (P < .01). Concerning global KJP, it was reduced by both treatments after 3 days and 1 week of the intervention (P < .001), being less with B-Turmactive after 1 week (P = .012 vs. 3 weeks). Although no intertreatment differences were observed, only B-Turmactive decreased high-sensitivity C-reactive protein levels (P = .045) at 1 week, which indicates a prompt analgesic effect mediated by a decrease in inflammatory status.
-
Treatment of autoimmune hemolytic anemia: real world data from a reference center in Mexico
José Carlos Jaime-Pérez,Patrizia Aguilar-Calderón,Lorena Salazar-Cavazos,Andrés Gómez-De León,David Gómez-Almaguer 대한혈액학회 2019 Blood Research Vol.54 No.2
BackgroundWarm autoimmune hemolytic anemia (w-AIHA) is an uncommon disease with heteroge-neous response to treatment. Steroids are the standard treatment at diagnosis, whereas rituximab has recently been recommended as the second-line therapy of choice. Our main objective was to document the response to treatment in patients with newly diag-nosed w-AIHA, including the effectiveness of low-dose rituximab as frontline treatment and for refractory disease.MethodsPatients with w-AIHA from 2002 to 2017 were included. Relapse-free survival (RFS), prob-ability of maintained response (MR), and time-to-response were analyzed using the Kaplan‒Meier method. Response was classified as complete, partial, and no response.ResultsWe included 64 adults with w-AIHA (39 women and 25 men). The median age was 37 (16‒77) years. Response rates to steroids alone were 76.7%, rituximab plus steroids, 100%; and cyclophosphamide, 80%. RFS with steroids at 6, 36, and 72 months was 86.3%, 65.1%, and 59.7%, respectively. Eighteen patients received rituximab at 100 mg/wk for 4 weeks plus high-dose dexamethasone as first-line therapy, with RFS at 6, 36, and 72 months of 92.3%, 58.7% and 44.1%, respectively. Eight patients refractory to several lines of therapy were treated with low-dose rituximab, and all achieved a response (three com-plete response and five partial response) at a median 16 days (95% confidence interval, 14.1‒17.8), with a 75% probability of MR at 103 months; the mean MR was 81.93±18months.ConclusionOutcomes of w-AIHA treatment were considerably heterogeneous. Low rituximab doses plus high dexamethasone doses were effective for refractory disease.
연관 검색어 추천
이 검색어로 많이 본 자료
활용도 높은 자료
